The IACT project (FP7) website is up and running

07-09-2015

LeadArtis is a partner of the IACT (Immunostimulatory Agonist Antibodies for Cancer Therapy) 6.9M€ funding consortium (Project Number: 602262). The IACT is an interdisciplinary platform that involves a total of 10 partners with long-standing expertise in agonist immunostimulatory antibodies (IS-Abs), from research institutions and small-medium enterprises (SEM) located in five European countries (Germany, Italy, Spain, Sweden and United Kingdom). Recently the website regarding this project (http://www.iact-project.eu/has been elaborated and is now ready for its visualization. We find the information included in the site relevant and a good basis to start interacting with other immunotherapy-oriented EU-projects, companies and research groups.

The IACT program aims to translate the agonist IS-Ab concept into clinical treatments. Two ongoing clinical trials are pivotal to bring forward the pre-clinical Proof of Concept in which striking therapeutic impact with agonist IS-Abs has been obtained. A parallel SME-driven effort will aim at the development of 2nd generation agonist IS-Abs with superior therapeutic index. In this regard, LeadArtis will apply its TrimerbodyTM technology to the development of optimized agonist IS-Abs and for strengthening the IACT agonist IS-Ab pipeline.

Latest News

LeadArtis participates in the fourth Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting in London (UK)
31-10-2017

The fourth IACT review meeting took place on October 25-26, 2017 in London, United Kingdom....

LeadArtis discloses ATTACK, a novel bispecific T cell-recruiting antibody approach for cancer immunotherapy
15-01-2018

LeadArtis´scientists, in collaboration with other prime...

Leadartis successfully accomplishes the TERET project
07-04-2017

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for...